P450-expression in brain tumors

Oncology Research

Volumn 11, Issue 11-12, 1999, Pages 523-528

  Knüpfer, Heike ^a,b   Knüpfer, Matthias M ^c   Hotfilder, Marc ^d   Preiß, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Paul Flechsig Institute of Brain Research   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cancer; CYP; Interleukins; Oxazaphosphorines; PCR

Indexed keywords

CYP2C9 PROTEIN, HUMAN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; MIXED FUNCTION OXIDASE; STEROID 16ALPHA MONOOXYGENASE; STEROID MONOOXYGENASE; TUMOR PROTEIN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BRAIN TUMOR; HUMAN; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; BRAIN NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MIXED FUNCTION OXYGENASES; NEOPLASM PROTEINS; RNA, MESSENGER; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0033290552     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Gonzalez, F. J. Molecular genetics of the P-450 superfamily. Pharmacol. Ther. 45:1-38; 1990.
2. Sladek, N. E. Metabolism of oxazaphosphorines. Pharmacol. Ther. 37:301-355; 1988.
3. Chang, T. K.; Weber, G. F.; Crespi, C. L.; Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53:5629-5637; 1993.
4. Walker, D.; Flinois, J. P.; Monkman, S. C.; Beloc, C.; Boddy, A. V.; Cholerton, S.; Daly, A. K.; Lind, M. J.; Pearson, A. D. J.; Beaune, P. H.; Idle, J. R. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 47:1157-1163; 1994.
5. Walker, D.; Raun, H. K.; Pearson, A. D. J.; Idle, J. R. Cytochrome P450 3A5 (CYP3A5) makes a significant contribution to the metabolism in vitro of cyclophosphamide and ifosfamide. Proc. Am. Assoc. Cancer Res. 36:2224; 1995.
6. Chang, T. K.; Yu, L.; Goldstein, J. A.; Waxman, D. J. Identification of the polymorphically expressed CYP2C19 and the wildtype CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7:211-221; 1997.
7. Schuetz, J. F.; Beach, D. L.; Guzelian, P. S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11-20; 1994.
8. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-423; 1994.
9. Krishna, D. R.; Klotz, U. Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet. 26:144-160; 1994.
10. McLemore, T. L.; Adelberg, S.; Liu, M. C.; McMahon, N. A.; Yu, S. J.; Hubbard, W. C.; Czerwinski, M.; Wood, T. G.; Storeng, R.; Lubet, R. A.; et al. Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J. Natl. Cancer Inst. 182:1333-1339; 1990.
11. Kivisto, K. T.; Fritz, P.; Linder, A.; Friedel, G.; Beaune, P.; Kroemer, H. K. Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochem. Cell Biol. 103:25-29; 1995.
12. Kivisto, K. T.; Linder, A.; Friedel, G.; Beaune, P.; Belloc, C.; Kroemer, H. K.; Fritz, P. Immunohistochemical localization of cytochrome P450 2E1 in human pulmonary carcinoma and normal bronchial tissue. Virchows Arch. 426:243-247; 1995.
13. Massaad, L.; de Waziers, I.; Ribrag, V.; Janot, F.; Beaune, P. H.; Morizet, J.; Gouyette, A.; Chabot, G. G. Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res. 52:6567-6575; 1992.
14. Fritz, P.; Behrle, E.; Beaune, P.; Eichelbaum, M.; Kroemer, H. K. Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: Immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase. Histochemistry 99:443-451; 1993.
15. Murray, G. I.; Weaver, R. J.; Paterson, P. J.; Ewen, S. W.; Melvin, W. T.; Burke, M. D. Expression of xenobiotic metabolizing enzymes in breast cancer. J. Pathol. 169:347-353; 1993.
16. Hellmold, H.; Rylander, T.; Magnusson, M.; Reiher, E.; Warner, M.; Gustafsson, J. A. Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasies. J. Clin. Endocrinol. Metab. 843:886-895; 1998.
17. McFadyen, M. C. E.; Melvin, W. T.; Murray, G. I. Cytochrome P450 in normal brain and brain tumors. Biochem. Soc. Trans. 25: 577; 1997.
18. Geng, J.; Strobel, H. W. Expression, induction and regulation of the cytochrome P450 monooxygenase system in the rat glioma C6 cell line. Brain Res. 784:276-283; 1998.
19. Abdel-Razzak, Z.; Loyer, P.; Fautrel, A.; Gautier, J. C.; Corcos, L.; Turlin, B.; Beaune, P.; Guillouzo, A. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol. 44:707-715; 1993.
20. Cribb, A. E.; Delaporte, E.; Kim, S. G.; Novak, R. F.; Renton, K. W. Regulation of cytochrome P-4501A and cytochrome P-4502E induction in the rat during the production of interferon alpha/beta. J. Pharmacol. Exp. Ther. 268:487-494; 1994.
21. Chen, J. Q.; Strom, A.; Gustafsson, J. A.; Morgan, E. T. Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: Comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6. Mol. Pharmacol. 47: 940-947; 1995.
22. Komori, M. A novel P450 expressed at the high level in rat brain. Biochem. Biophys. Res. Commun. 196:721-728; 1993.
23. Kivisto, K. T.; Griese, E. U.; Fritz, P.; Linder, A.; Hakkola, J.; Raunio, H.; Beaune, P.; Kroemer, H. K. Expression of cytochrome P 450 3A enzymes in human lung: A combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn Schmiedebergs Arch. Pharmacol. 353:207-212; 1996.
24. Huang, Z.; Fasco, M. J.; Figge, H. L.; Keyomarsi, K.; Kaminsky, L. S. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab. Dispos. 24:899-905; 1996.
25. Strobel, H. W.; Kawashima, H.; Geng, J.; Sequeira, D.; Bergh, A.; Hodgson, A. V.; Wang, H.; Shen, S. Expression of multiple forms of brain cytochrome P450. Toxicol. Lett. 82-83:639-643; 1995.
26. McFadyen, M. C. E.; Melvin, W. T.; Murray, G. I. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem. Pharmacol. 55:825-830; 1998.
27. Geng, J.; Strobel, H. W. Identification of cytochromes P450 1A2, 2A1, 2C7, 2E1 in rat glioma C6 cell line by RT-PCR and specific restriction enzyme digestion. Biochem. Biophys. Res. Commun. 197:1179-1184; 1993.
28. Nelson, D. R.; Koymans, L.; Kamataki, T.; Stegeman, J. J.; Feyereisen, R.; Waxman, D. J.; Waterman, M. R.; Gotoh, O.; Coon, M. J.; Estabrook, R. W.; Gunsalus, I. C.; Neben, D. W. P450 superfamily. Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42; 1996.
29. Cholerton, S.; Daly, A. K.; Idle, J. R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13:434-439; 1992.
30. Pichard, L.; Fabre, I.; Fabre, G.; Domergue, J.; Saint Aubert, B.; Mourad, G.; Maurel, P. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18:595-606; 1990.
31. Muntane-Relat, J.; Ourlin, J. C.; Domergue, J.; Maurel, P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22:1143-1153; 1995.
32. Sujita, K.; Okuno, F.; Tanaka, Y.; Hirano, Y.; Inamoto, Y.; Eto, S.; Arai, M. Effect of interleukin 1 (IL-1) on the levels of cytochrome P-450 involving IL-1 receptor on the isolated hepatocytes of rat. Biochem. Biophys. Res. Commun. 168:1217-1222; 1990.
33. Lee, J. C.; Simon, P. L.; Young, P. R. Constitutive and PMA-induced interleukin-1 production by the human astrocytoma cell line T24. Cell Immunol. 118:298-311; 1989.
34. van Meir, E.; Sawamura, Y.; Diserens, A. C.; Hamou, M. F.; de Tribolet, N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 50:6683-6688; 1990.
35. Poppenborg, H.; Knüpfer, M. M.; Galla, H-J.; Wolff, J. E. A. In vitro modulation of cisplatin resistance by cytokines. Cytokine 11: 689-695; 1999.
36. Yule, S. M.; Boddy, A. V.; Cole, M.; Price, L.; Wyllie, R.; Tasso, M. J.; Pearson, A. D.; Idle, J. R. Cyclophosphamide metabolism in children. Cancer Res. 15:803-809; 1995.
37. Genka, S.; Deutsch, J.; Stahle, P. L.; Shetty, U. H.; John, V.; Robinson, C.; Rapoport, S. I.; Greig, N. H. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother. Pharmacol. 27:1-7; 1990.
38. Heidemann, R. L.; Douglass, E. C.; Langston, J. A.; Krischer, J. P.; Burger, P. C.; Kovnar, E. H.; Kun, L. E.; Freidman, H. S.; Kadota, R. A phase II study of every other day high-dose ifosfamide in pediatric brain tumors. A pediatric oncology group study. J. Neurooncol. 25:77-84; 1995.
39. Chen, L.; Waxman, D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer. Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55:581-589; 1995.
40. Chen, L.; Waxman, D. J.; Chen, D.; Kufe, D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56:1331-1340; 1996.
41. Chen, L.; Yu, L. J.; Waxman, D. J. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 57:4830-4837; 1997.
42. Manome, Y.; Wen, P. Y.; Chen, L.; Tanaka, T.; Dong, Y.; Yamazoe, M.; Hirshowitz, A.; Kufe, D. W.; Fine, H. A. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther. 3:513-520; 1996.
43. Jounaidi, Y.; Hecht, J. E. D.; Waxman, D. J. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 58:4391-4401; 1998.
44. Pope, I. M.; Poston, G. J.; Kinsella, A. R. The role of the by-stander effect in suicide gene therapy. Eur. J. Cancer 33:1005-1016; 1997.
45. Wei, M. X.; Tamiya, T.; Rhee, R. J.; Breakfield, X. O.; Chiocca, E. A. Diffusible cytotoxic metabolites to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin. Cancer Res. 1:1171-1177; 1995.
46. Wang, S. L.; Huang, J.; Lai, M. D.; Tsai, J. J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42; 1995.
47. Tada, M.; Diserens, A. C.; Desbaillets, I.; de Tribolet, N. Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J. Neurosurg. 80:1063-1073; 1994.